ABSTRACT
In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 +/- 0.25 to 0.50 +/- 0.18 and 0.29 +/- 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 +/- 65 to 208 +/- 23 microm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Angiogenesis Inhibitors/administration & dosage , Antibodies, Monoclonal, Humanized/administration & dosage , Central Serous Chorioretinopathy/drug therapy , Follow-Up Studies , Intravitreal Injections , Tomography, Optical Coherence , Treatment Outcome , Visual Acuity/drug effectsABSTRACT
The pictures of 78 cases (86 eyes) of central serous choroidoretinopathy taken by fluorescein fundus angiography were anslyzed in this article. The results based on the observation of leaking shape showed that the jet type was more during the early period of illness, whereas the spread type was more during the late period of illness. It is significant to diagnose and treat central serous choroidoretinopathy with fluorescein fundus angiography.